Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Kenneth K. Tanabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1920-3417; OpenAlex author ID A5043519976. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2026.116500↗
  2. Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment. Co-author DOI 10.1158/0008-5472.can-24-3384↗
  3. Allysine-Targeted Molecular MRI Enables Early Prediction of Chemotherapy Response in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3548↗
  4. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  5. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  6. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  7. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Co-author DOI 10.1242/dmm.034793↗
  8. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Co-author DOI 10.1016/j.canlet.2017.08.028↗
  9. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Co-author DOI 10.1016/j.surg.2013.05.004↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peter D. Caravan · 5 shared papers, 2018–2025 · strength 0.70
  2. Ibrahim Ragab Eissa · 2 shared papers, 2025–2026 · strength 0.58
  3. Genevieve Marie Boland · 2 shared papers, 2024–2026 · strength 0.54
  4. Motaz Qadan · 3 shared papers, 2020–2025 · strength 0.42
  5. Theodore Sunki Hong · 3 shared papers, 2017–2024 · strength 0.36
  6. Shadi Abdar Esfahani · 2 shared papers, 2024 · strength 0.35
  7. Hua Ma · 2 shared papers, 2024 · strength 0.35
  8. Nabeel M. Bardeesy · 3 shared papers, 2018–2025 · strength 0.35
  9. Carlos Fernández-del Castillo · 2 shared papers, 2023–2024 · strength 0.31
  10. Colin D. Weekes · 2 shared papers, 2023–2024 · strength 0.31
  11. Michael D. Lanuti · 3 shared papers, 2018–2024 · strength 0.30
  12. Veronica Clavijo Jordan · 2 shared papers, 2020–2025 · strength 0.27
  13. Bryan C. Fuchs · 4 shared papers, 2013–2020 · strength 0.24
  14. Cristina Rosa Ferrone · 2 shared papers, 2017–2023 · strength 0.21
  15. Keith D. Lillemoe · 2 shared papers, 2017–2023 · strength 0.21
  16. Andrew Scott Liss · 1 shared paper, 2024 · strength 0.20
  17. Stuti G. Shroff · 1 shared paper, 2025 · strength 0.19
  18. Andrew Louis Warshaw · 1 shared paper, 2023 · strength 0.15
  19. Florence K. Keane · 1 shared paper, 2023 · strength 0.15
  20. Alicia Smart · 1 shared paper, 2023 · strength 0.15
  21. David P. Ryan · 1 shared paper, 2023 · strength 0.15
  22. Lawrence Scott Blaszkowsky · 1 shared paper, 2023 · strength 0.15
  23. Jennifer Yon-Li Wo · 1 shared paper, 2023 · strength 0.15
  24. Derek J. Erstad · 2 shared papers, 2018–2020 · strength 0.15
  25. Cristina R. Ferrone · 2 shared papers, 2018–2020 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.